AUS
NZ
UK
CA
USA
IND
On August 6, 2024, Faron Pharmaceuticals Ltd. (LSE:FARN), a clinical-stage biopharmaceutical firm focused on innovative cancer therapies, announced the appointment of Dr. Petri Bono as its new Chief Medical Officer (CMO). Dr. Bono will officially begin his role on August 15, 2024.
Previous Roles
Dr. Bono brings extensive experience in oncology and medical leadership to Faron. Previously, he served as the Chief Medical Officer and a member of the executive team at Terveystalo, Finland’s largest private healthcare provider. Before that, he was the Chief Medical Officer at Helsinki University Hospital and held several significant positions at the Comprehensive Cancer Center, including Director and Physician-in-Chief. His academic credentials include a role as Associate Professor of Cancer Biology at the University of Helsinki. Dr. Bono has contributed to numerous oncology trials, ranging from early Phase 1 studies to Phase 3, and has authored 102 peer-reviewed articles in prominent medical journals.
Expertise in Oncology
Dr. Bono’s research has predominantly focused on molecular and immunological oncology. His extensive background in translational and clinical studies of targeted therapies and applied immunology aligns well with Faron’s focus on immuno-oncology. His expertise is expected to enhance Faron's efforts in advancing its novel myeloid cell-targeting immunotherapies, particularly in the treatment of solid tumors.
Focus on Bexmarilimab
Dr. Bono expressed enthusiasm about Faron's lead asset, bexmarilimab. He noted that bexmarilimab is a leader in macrophage reprogramming and holds potential for treating various cancers. Dr. Bono highlighted the challenge of treatment resistance in solid tumors and expressed his commitment to advancing Faron’s immunotherapy programs to potentially broaden the impact of these therapies.
CEO's Statement
Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals, welcomed Dr. Bono’s appointment. Jalkanen highlighted that Dr. Bono’s expertise will be particularly valuable as the company plans to expand its focus into solid tumors. He emphasized that Dr. Bono’s experience will help maximize Faron’s capabilities in both solid tumors and hematological malignancies. Jalkanen also noted that this move represents a strategic enhancement of the company's development and partnership strategies, which aims to create additional value for patients and investors.
Acknowledgment of Interim CMO
Dr. Birge Berns, who has been serving as the acting CMO seconded by tranScrip Ltd., will continue to play a crucial role in Faron’s medical leadership. Dr. Berns has been instrumental in advancing bexmarilimab and will continue to contribute to the development and regulatory strategy of the drug. Jalkanen expressed gratitude for Berns’ efforts and acknowledged the ongoing partnership with tranScrip.
Company Background
Faron Pharmaceuticals Ltd. is focused on developing cutting-edge biopharmaceuticals, particularly in immuno-oncology. The company is engaged in advancing therapies that target myeloid cells to enhance anti-tumor immunity. Faron’s mission involves pushing the boundaries of cancer treatment through innovative approaches and strategic collaborations.
